If you have been reading about bioavailability and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
== History == Tom Kudirka, originally from Omaha, Nebraska, and an alumnus of Bellevue West High School, had studied business information systems and electronics before moving to Tulsa to work for Lucent Technologies as a field engineer. Thereafter, he had established multimedia companies, including one dealing with speech recognition. Because Kudirka "thought he was bored", he founded 2015 in Tulsa in May 1997. The name was said to have been chosen for an undisclosed "very significant" reason, although Kudirka later said he did not know what it meant. Kudirka recruited developers he had discovered online and had them relocate to Tulsa. The designer Zied Rieke was the first hire. Through Kudirka's connections with Ritual Entertainment and its CEO, 2015 came to develop Wages of Sin, an expansion pack for Ritual Entertainment's 1998 game Sin. It was released in February 1999. On April 3, 2000, 2015 announced the opening of its Trainwreck Studios division for budget-price games with a wider target audience. The first game therein, Laser Arena, was designed to be playable by Kudirka's three-year-old son and released in September 2000. 2015 was simultaneously working on its third game, Heavy Gear Extreme. The company grew to 15 people, requiring it to expand its office space at 8282 South Memorial Drive. The second Trainwreck Studios game, CIA Operative: Solo Missions, was released in May 2001. 2015 was reported as developing Half-Life: Hostile Takeover as an expansion for Half-Life in November 1999.
==== Nanodiamonds ==== Nanodiamonds (NDs) are carbon nanoparticles which can vary from ~4-100 nm in diameter. NDs are typically formed in two ways: from micron-sized diamond particles under high-pressure high-temperature conditions, called high-pressure high-temperature nanodiamonds (HPHT NDs) and by shock-wave compression, called detonation nanodiamonds (DNDs). The surfaces of these NDs can be modified by processes such as oxidation and aminification to alter adsorption properties.
Arrived from Mexico on the blessed ground of this republic, whose executive powers were placed in your hands, I feel it my pleasant duty to present my respects and express my high admiration for your writings, your actions, and the liberalism of your ideas, which have inspired me from my earliest youth. I flatter myself in the expectation of expressing my sentiments orally to you, remitting at the same time the attached parcel, which my friend the Consul of the United States in Havana asked me to send to you[...] For moral reasons I could not resist seeing the United States and enjoying the consoling aspects of a people who under stand the precious gift of Liberty. I hope to be able to present my personal respects and admiration to one who contemplates philosophically the troubles of two continents. [...] I am quite unaware whether you know of me already through my work on galvanism and my publications in the memoirs of the Institut National in Paris. As a friend of science, you will excuse the indulgence of my admiration. I would love to talk to you about a subject that you have treated so ingeniously in your work on Virginia, the teeth of mammoth which we too dis covered in the Andes[...] During his wait for a response from President Jefferson, Humboldt was honored by the American Philosophical Society, of which Jefferson was the President. This society, founded in 1743 by Benjamin Franklin, was a center for scientific inquiry in the Republic. Humboldt mingled with members such as Dr.
Sources: en.wikipedia.org
By the mid-1990s, several GH companies had sponsored or publicized research into the quality of life of adults with severe GH deficiency. Most were people having been treated with GH in childhood for severe deficiency. Many of them stopped injections as they reached their final heights in the low-normal range. However, as adults in their 30s and 40s, these people, who had been children with growth hormone deficiency, were now adults with growth hormone deficiency and had more than their share of common adult problems: reduced physical, mental, and social energy, excess adipose and diminished muscle, diminished libido, poor bone density, higher cholesterol levels, and higher rates of cardiovascular disease. Research trials soon confirmed that a few months of GH could improve nearly all of these parameters. However, despite marketing efforts, most GH-deficient adults remain untreated. Though GH use was slow to be accepted among adults with GH deficiency, similar research to see if GH treatment could slow or reverse some of the similar effects of aging attracted much public interest. The most publicized trial was reported by Daniel Rudman in 1990. As with other types of hormone supplementation for aging (testosterone, estrogen, DHEA), confirmation of benefit and accurate understanding of risks has been only slowly evolving. In 1997, Ronald Klatz of the American Academy of Anti-Aging Medicine published Grow Young With HGH: The Amazing Medically Proven Plan To Reverse the Effects Of Aging, an uncritical touting of GH as the answer to aging.
Over the course of the Second World War, about 87,000 Indian soldiers were killed. In this period, 31 Indians were awarded the Victoria Cross (See: Indians in 'List of Victoria Cross Recipients by Nationality'). Out of the 252 Distinguished Service Orders awarded to the British Indian Army, at least 13 were awarded to native officers (See: South Asian Companions of the Distinguished Service Order).
=== Polygamy === Both male and female D. melanogaster flies act polygamously (having multiple sexual partners at the same time). In both males and females, polygamy results in a decrease in evening activity compared to virgin flies, more so in males than females. Evening activity consists of those in which the flies participate other than mating and finding partners, such as finding food. The reproductive success of males and females varies, because a female only needs to mate once to reach maximum fertility. Mating with multiple partners provides no advantage over mating with one partner, so females exhibit no difference in evening activity between polygamous and monogamous individuals. For males, however, mating with multiple partners increases their reproductive success by increasing the genetic diversity of their offspring. This benefit of genetic diversity is an evolutionary advantage because it increases the chance that some of the offspring will have traits that increase their fitness in their environment. The difference in evening activity between polygamous and monogamous male flies can be explained with courtship. For polygamous flies, their reproductive success increases by having offspring with multiple partners, and therefore they spend more time and energy on courting multiple females. On the other hand, monogamous flies only court one female, and expend less energy doing so. While it requires more energy for male flies to court multiple females, the overall reproductive benefits it produces has kept polygamy as the preferred sexual choice.
=== Since Silk Road === From late 2013 through to 2014, new markets started launching with regularity, such as the Silk Road 2.0, run by the former Silk Road site administrators, as well as the Agora marketplace. Such launches were not always a success; in February 2014 Utopia, the highly anticipated market based on Black Market Reloaded, opened only to shut down eight days later following rapid actions by Dutch law enforcement. February 2014 also marked the short lifespans of Black Goblin Market and CannabisRoad, two sites which closed after being deanonymized without much effort. November 2014 briefly shook the darknet market ecosystem, when Operation Onymous, executed by the United States' FBI and UK's National Crime Agency, led to the seizure of 27 hidden sites, including Silk Road 2.0, one of the largest markets at the time, as well 12 smaller markets and individual vendor sites. By September 2014, Agora was reported to be the largest market, avoiding Operation Onymous; as of April 2015, Agora has gone on to be the largest overall marketplace, with more listings than the Silk Road at its height. Further market diversification occurred in 2015, as did further developments around escrow and decentralization. In March 2015, the Evolution marketplace performed an "exit scam", stealing escrowed bitcoins worth $12 million, half of the ecosystem's listing market share at that time. The closure of Evolution led to users redistributing to Black Bank and Agora.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.